NUIG to co-lead clinical trial on diabetic wounds

Galway Bay fm newsroom – NUI Galway is to co-lead a clinical trial to examine diabetic wounds. The project will research a treatment for non-healing ulcerating wounds in patients will the condition. Despite the use of approved anti-diabetic agents, diabetes still leads to six progressive complications including wound ulceration. Orbsen Therapuetics, a spin-out company from NUIG's Regenerative Medicine Institute, has been selected for the EU Framework funded safety trial. The REDDSTAR project is being co-ordinated by Professor Timothy O'Brien, Dean of Medicine and Director REMEDI at NUIG. The company has developed a unique method of isolating therapeutic cells from human issues at high purity levels. Teams based in Galway, Berlin, Belfast, Munich and Porto have been testing the product against the current standard cell therapy. NUI Galway and the Steno Diabetes Centre based in Copenhagen will lead the trial in 2015. The post NUIG to co-lead clinical trial on diabetic wounds appeared first on Galway Bay FM.